Predictive value of LCP1 and ADPGK for immune-related adverse events across multiple cancer types in patients receiving immunotherapy-based regimens.

IF 4.5 2区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Acta biochimica et biophysica Sinica Pub Date : 2026-09-25 DOI:10.3724/abbs.2026016

Xi Zhang, Yaqian Li, Li Zhang, Hongyu Liu, Wei Sun, Junhua Li, Dan Xue, Fan Zhang, Yuting Bai, Jing Zhang, Xing Gou, Dongzi Pang, Xueqin Zeng, Shuqing Wei

引用次数: 0

查看原文本刊更多论文

LCP1和ADPGK对接受免疫治疗方案的多种癌症类型患者免疫相关不良事件的预测价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta biochimica et biophysica Sinica 生物-生化与分子生物学

CiteScore

5.00

自引率

5.40%

发文量

170

审稿时长

3 months

期刊介绍： Acta Biochimica et Biophysica Sinica (ABBS) is an internationally peer-reviewed journal sponsored by the Shanghai Institute of Biochemistry and Cell Biology (CAS). ABBS aims to publish original research articles and review articles in diverse fields of biochemical research including Protein Science, Nucleic Acids, Molecular Biology, Cell Biology, Biophysics, Immunology, and Signal Transduction, etc.